Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $DNLI
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/7/2025 | $41.00 → $33.00 | Overweight | Morgan Stanley |
2/11/2025 | $31.00 | Buy | Deutsche Bank |
1/7/2025 | $31.00 | Outperform | Robert W. Baird |
1/3/2025 | Outperform | William Blair | |
12/16/2024 | $37.00 | Hold → Buy | Stifel |
10/10/2024 | Mkt Perform | Raymond James | |
10/7/2024 | Overweight → Neutral | Cantor Fitzgerald | |
12/13/2023 | $32.00 | Buy | Citigroup |
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights. "In 2024, we made significant strides across our portfolio, particularly with our Enzyme Transport Vehicle (ETV) programs, achieving a path to a potential accelerated approval for our lead program in MPS II," said Ryan Watts, Ph.D., CEO of Denali. "In 2025, we will continue expanding our capabilities as we prepare for our first potential product launch of tividenofusp alfa. In addition, we are prioritizing opportunities to expand and accelerate our TV portfolio and a
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued improvement in hearing, cognition and adaptive behaviorLong-term safety data with median follow-up of two years, and out to more than four years, demonstrate that tividenofusp alfa was generally well tolerated Regulatory submission for accelerated approval is planned for early 2025; U.S. launch preparation is ongoing to deliver tividenofusp alfa to families with MPS II in late 2025 or early 2026 SOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), today announced the primary analysis of the Phase 1/2
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), today announced upcoming oral (platform) and poster presentations at the 21st Annual WORLDSymposium™, which will be held February 3-7, 2025, in San Diego, California. The oral presentation includes clinical results related to its Hunter syndrome (MPS II) investigational therapeutic, tividenofusp alfa (DNL310). Tividenofusp alfa is enabled by the Denali TransportVehicle™ platform, which is designed to effectively deliver enzyme, oligonucleotide, or antibody therapeutics to all tissues in the body, including the brain by crossing the blood-brain barrier. The presentation schedule at WORLDS
Morgan Stanley resumed coverage on Denali Therapeutics with a new price target
Morgan Stanley resumed coverage of Denali Therapeutics with a rating of Overweight and set a new price target of $33.00 from $41.00 previously
Deutsche Bank initiated coverage on Denali Therapeutics with a new price target
Deutsche Bank initiated coverage of Denali Therapeutics with a rating of Buy and set a new price target of $31.00
Robert W. Baird initiated coverage on Denali Therapeutics with a new price target
Robert W. Baird initiated coverage of Denali Therapeutics with a rating of Outperform and set a new price target of $31.00
Chief Medical Officer Ho Carole sold $308,291 worth of shares (15,162 units at $20.33), decreasing direct ownership by 8% to 175,673 units (SEC Form 4)
4 - Denali Therapeutics Inc. (0001714899) (Issuer)
COFO and Secretary Schuth Alexander O. sold $308,291 worth of shares (15,162 units at $20.33), decreasing direct ownership by 6% to 244,308 units (SEC Form 4)
4 - Denali Therapeutics Inc. (0001714899) (Issuer)
President and CEO Watts Ryan J. sold $750,955 worth of shares (36,916 units at $20.34), decreasing direct ownership by 13% to 253,071 units (SEC Form 4)
4 - Denali Therapeutics Inc. (0001714899) (Issuer)
Denali Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
8-K - Denali Therapeutics Inc. (0001714899) (Filer)
SEC Form S-8 filed by Denali Therapeutics Inc.
S-8 - Denali Therapeutics Inc. (0001714899) (Filer)
Denali Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Denali Therapeutics Inc. (0001714899) (Filer)
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director. O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and phar
DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING
Banks was Most Recently the President and CEO of Tyson Foods and has been a Board Member of Indigo since July 2022 Company Closes Financing Round at Nearly $270 Million Indigo Also Appoints Nader Bekhouche and Noubar Afeyan to Board of Directors CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag, effective February 1, 2024. Banks will also continue as an Indigo board member, a role he has held since July 2022. Indigo also announced the appointments of Nader Be
Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders
Memorandum of Understanding with UK Government Outlines Areas of Cooperation CAMBRIDGE, Mass. and LONDON, Nov. 27, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia with a focus on breakthrough innovation. The event marked Flagship's public announcement of its strategic commitment to the UK life sciences ecosystem a week after launching Quotient Therapeutics, its first company located in both the UK and US.
SEC Form SC 13G filed by Denali Therapeutics Inc.
SC 13G - Denali Therapeutics Inc. (0001714899) (Subject)
Amendment: SEC Form SC 13G/A filed by Denali Therapeutics Inc.
SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)
Amendment: SEC Form SC 13G/A filed by Denali Therapeutics Inc.
SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)